A new formulation of levodopa/carbidopa received authorization from the European Commission for adults with Parkinson's disease and moderate to advanced motor fluctuations. The treatment, called Produodopa and developed by the pharmaceutical company, is administered through continuous subcutaneous infusion, offering an alternative to traditional oral administration methods.
The medication aims to provide patients with more hours of "good motor control," reducing the fluctuations between periods of mobility and immobility that characterize the disease. The continuous infusion allows for more stable levels of the active substance in the body throughout the day.
The authorization is based on clinical study data that demonstrated the efficacy and safety of the treatment. This approval represents a new therapeutic option for patients who cannot adequately manage their symptoms with conventional oral medication.
Parkinson's disease affects millions of people in Europe and represents a significant challenge for health systems. This new therapeutic approach comes to address an unmet medical need, offering neurologists and patients an additional tool in the fight against the disease.
